Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Leuprorelin depot - AbbVie/Takeda

Drug Profile

Leuprorelin depot - AbbVie/Takeda

Alternative Names: Carcinil; Enanton Depot; Enanton-Gyn; Enantone; Enantone Depot; Enantone LP; Ginecrin; Leuplin; Leuplin SR; Leuprolide acetate depot; Leuprolide acetate for depot suspension; Leuprolide depot; leuprorelide for depot suspension; Leuprorelin acetate depot; Lucrin; Lucrin Depot; Lupron Depot; Lupron Depot-PED; Procren Depot; Procrin; Prostap SR; TAP-144-SR; Trenantone-Gyn

Latest Information Update: 16 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Takeda
  • Developer AbbVie; Norwood Abbey; Takeda
  • Class Antineoplastics; Gonadotropins; Infertility therapies; Oligopeptides; Pituitary hormone releasing hormones
  • Mechanism of Action Gonadotropin releasing hormone stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Breast cancer; Endometriosis; Menorrhagia; Precocious puberty; Prostate cancer; Uterine leiomyoma
  • Discontinued Haematological disorders

Most Recent Events

  • 24 Oct 2018 Phase-III clinical trials in Precocious puberty in Puerto Rico (IM) (NCT03695237)
  • 09 Oct 2018 AbbVie plans a phase III trial for Precocious Puberty in USA and Puerto Rico , (NCT03695237)
  • 01 Nov 2016 Takeda completes a phase III trial in Prostate cancer (12-month formulation) in France (SC) (NCT02085252)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top